A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9400430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1996cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

  1995cited by this paper
• RS-61443: rescue therapy in refractory kidney transplant rejection.

  1993cited by this paper
• One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation.

  1993cited by this paper
• Risk factors for chronic rejection in renal allograft recipients.

  1993cited by this paper
• International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.

  1993cited by this paper
• THE IMPACT OF ACUTE REJECTION EPISODES ON LONG‐TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENS

  1993cited by this paper
• Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy.

  1993cited by this paper
• Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single Center

  1993cited by this paper
• A RANDOMIZED TRIAL OF CYCLOSPORINE AND PREDNISOLONE VERSUS CYCLOSPORINE, AZATHIOPRINE, AND PREDNISOLONE IN PRIMARY CADAVERIC RENAL TRANSPLANTATION

  1992cited by this paper
• THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTS

  1992cited by this paper
• Rejection episodes.

  1992cited by this paper
• RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection

  1992cited by this paper
• RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1

  1992cited by this paper
• Survival trends in long-term first cadaver-donor kidney transplants.

  1991cited by this paper
• RS-61443--a new, potent immunosuppressive agent.

  1991cited by this paper
• Tolerance induction in adult mice: cyclosporine inhibits RS-61443-induced tolerance.

  1991cited by this paper
• RS-61443 reverses acute allograft rejection in dogs.

  1991cited by this paper
• RS-61443 allows islet allografting and specific tolerance induction in adult mice.

  1990cited by this paper
• Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.

  1990cited by this paper

• Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

  2024cites this paper
• Systemic Immunosuppression in Cornea and Ocular Surface Disorders: A Ready Reckoner for Ophthalmologists

  2021cites this paper
• Immunosuppression for Lung Transplantation: Current and Future

  2018cites this paper
• Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation

  2016cites this paper
• B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation.

  2013cites this paper
• The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.

  2011cites this paper
• Mycophenolate mofetil: An update.

  2009cites this paper
• Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal.

  2007cites this paper
• The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.

  2007cites this paper
• [Infectious complications in using mofetil micofenolate in patients with renal allotransplant].

  2005cites this paper
• Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients?

  2005cites this paper
• Low toxicity immunosuppressive protocols in renal transplantation.

  2004cites this paper
• Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease.

  2004cites this paper
• Selective use of mycophenolate mofetil in renal transplant patients in Indian scenario.

  2004cites this paper
• UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE CIÊNCIAS MÉDICAS PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS MÉDICAS: NEFROLOGIA

  2003influential citation
• Dialysis, kidney transplantation, or pancreas transplantation for patients with diabetes mellitus and renal failure: a decision analysis of treatment options.

  2003cites this paper
• A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil

  2003cites this paper
• Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil.

  2002cites this paper
• New developments in immunosuppressive therapy in renal transplantation

  2002cites this paper
• Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.

  2002cites this paper
• CYCLOSPORINE MICROEMULSION– AND MYCOPHENOLATE MOFETIL–RELATED LYMPHOID AGGREGATES ARE NOT ASSOCIATED WITH ACUTE REJECTION

  2001cites this paper
• Expresión del "Transforming Growt Factor"(TGF)?1 en el síndrome de isquemia-reperfusión en un modelo de trasplante experimental a corazón parado en cerdo.

  2001cites this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cites this paper
• Immunosuppressive agents in organ transplantation: past, present, and future.

  2000cites this paper
• The use of mycophenolate mofetil in transplant recipients.

  2000cites this paper
• Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation.

  2000cites this paper
• Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.

  2000cites this paper
• Diabetic rats transplanted with adult porcine islets and immunosuppressed with cyclosporine A, mycophenolate mofetil, and leflunomide remain normoglycemic for up to 100 days.

  2000cites this paper
• The role of transforming growth factor beta in chronic renal allograft nephropathy.

  2000cites this paper
• Mycophenolate mofetil for Crohn's disease?

  1999cites this paper
• Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.

  1999cites this paper
• Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.

  1999cites this paper